# An Eight-week Randomized,Double-blind Study to Evaluate the Efficacy and Safety of Fixed-dose Combinations of T80+A5 Versus A5 Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With A5 Monotherapy

Study · id `cardio:ct-nct01103960` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01103960](<https://clinicaltrials.gov/study/NCT01103960>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01103960

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 324 participants.

## Technical summary

Registry record NCT01103960. Randomized; double masking; primary purpose treatment. Start 2010-07 (registry gives no type); primary completion 2011-08 (actual). Results posted on 2012-09-20.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 324 participants (enrolled count; ClinicalTrials.gov record NCT01103960, source copy `cardio:ctgov-nct01103960-2014-06-27`, retrieved 2026-10-26)
- Start date: 2010-07 (registry gives no type) (ClinicalTrials.gov record NCT01103960, source copy `cardio:ctgov-nct01103960-2014-06-27`, retrieved 2026-10-26)
- Primary completion: 2011-08 (actual) (ClinicalTrials.gov record NCT01103960, source copy `cardio:ctgov-nct01103960-2014-06-27`, retrieved 2026-10-26)
- Completion: Not reported
- Results first posted: 2012-09-20 (ClinicalTrials.gov record NCT01103960, source copy `cardio:ctgov-nct01103960-2014-06-27`, retrieved 2026-10-26)
- Countries: China; Malaysia; Philippines (ClinicalTrials.gov record NCT01103960, source copy `cardio:ctgov-nct01103960-2014-06-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01103960-2014-06-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: An Eight-week Randomized,Double-blind Study to Evaluate the Efficacy and Safety of Fixed-dose Combinations of T80+A5 Versus A5 Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With A5 Monotherapy
- Condition: Hypertension
- Intervention (Drug): Telmisartan80mg+Amlodipine5mg
- Intervention (Drug): amlodipine 5mg
- Intervention (Drug): Telmisartan80mg+Amlodipine 5mg
- Lead sponsor: Boehringer Ingelheim
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Boehringer Ingelheim (`cardio:boehringer-ingelheim`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: A randomized, double-blind study to evaluate the efficacy and safety of a single-pill combination of telmisartan 80 mg/amlodipine 5 mg versus amlodipine 5 mg in hypertensive Asian patients (`cardio:pubmed-24391142`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 71d052d8b3e4223d510bcbba26a10b3b0636ed2b9c3851ffdbdba2996dbd8c63
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
